Sumary Decreased expression of E-cadherin (E-CD). a homotypic intercellular adhesion molecule, is considered to elicit detachment of tumour cells from primary lesions, which is the first stage of metastasis. Since renal cell cancer (RCC) shows a relatively high frequency of metastasis, we focused our interest on E-CD expression in RCC and its clinicopathological implications. We examined E-CD expression in normnal kidney and RCC by immunohistochemical staining. In normal kidney, E-CD expression was localised in distal tubules and collecting ducts. In RCC, 20 of 106 primary lesions (18.9%) expressed E-CD. whereas none showed positive staining for eight metastatic lesions. There was a statistically significant correlation between loss of E-CD expression and advanced stages of RCC. Kaplan-Meier analysis showed better prognosis in the group with preserved E-CD expression than without E-CD expression (Cox -Mantel test. P = 0.022, the average follow-up was 32 months or until death). This study suggests that the patients with decreased E-CD expression may be associated with metastasis, resulting in poor prognosis. However, frequency of E-CD expression in RCC is lower than in other cancers, which may be derived from the localised distribution of E-CD expression in normal kidney.Keywords E-cadherin; renal cell cancer: metastasis It is well known that cadherins, a family of Ca2+-dependent intercellular adhesion molecules, play essential roles in organogenesis and in the maintenance of normal structure and function (Behrens et al., 1985;Eidelman et al., 1989;Takeichi, 1991). Recently, E-cadherin (E-CD), a subclass of cadherins, has come to be considered to be important as an inhibitory factor in metastasis (Behrens et al., 1985; Frixen et al., 1991;Takeichi, 1991 (1991) showed that loss of E-CD can generate an invasive phenotype, which can be prevented by transfection with E-CD cDNA. Clinically, the correlation between decreased E-CD expression and advanced stages or dedifferentiation was also reported in a variety of tumours (Frixen et al., 1991;Shiozaki et al., 1991; Oka et al., 1992;Umbas et al., 1992;Bringuier et al., 1993; Oka et al., 1993;Terpe et al., 1993). However, reports in relation to the prognosis of malignant tumours have been rare until now (Bringuier et al., 1993 Immunohistochemical staining Anti-E-CD monoclonal antibody (HECD-1, Takara Biomedicals, Tokyo, Japan) was used in this study, and immunoperoxidase staining was performed by modifying the streptavidin-biotin bridge technique described previously (Katagiri et al., 1993